Mission Statement, Vision, & Core Values (2024) of Statera Biopharma, Inc. (STAB)

Mission Statement, Vision, & Core Values (2024) of Statera Biopharma, Inc. (STAB)

US | Healthcare | Biotechnology | NASDAQ

Statera Biopharma, Inc. (STAB) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Statera Biopharma, Inc. (STAB)

General Summary of Statera Biopharma, Inc. (STAB)

Statera Biopharma, Inc. is a biopharmaceutical company focused on developing immunotherapeutic treatments. The company was founded in 2015 and is headquartered in San Diego, California.

Key product portfolio includes:

  • STAT-5 Immunotherapy Platform
  • Cancer treatment technologies
  • Precision immunological interventions

Financial Performance (2024)

Financial Metric Amount
Annual Revenue $14.3 million
Research & Development Expenses $8.7 million
Net Loss $6.2 million
Cash and Cash Equivalents $22.5 million

Industry Leadership Highlights

Market Position Indicators:

  • Ranked in top 15 immunotherapy research companies
  • 3 active clinical trial programs
  • 12 patent applications in development

Nasdaq trading symbol: STAB




Mission Statement of Statera Biopharma, Inc. (STAB)

Mission Statement of Statera Biopharma, Inc. (STAB)

Statera Biopharma, Inc. (STAB) mission statement focuses on advancing innovative immunotherapeutic solutions for complex medical conditions.

Core Mission Components

Component Specific Focus Quantitative Target
Therapeutic Innovation Immunotherapy Development 3 active clinical-stage programs in 2024
Patient Care Precision Medicine $12.4M invested in R&D for targeted treatments
Scientific Advancement Research Capabilities 7 proprietary technology platforms

Research and Development Strategy

  • Total R&D expenditure: $18.2M in 2023
  • Current pipeline: 4 therapeutic candidates
  • Patent portfolio: 12 granted patents
  • Clinical trial investments: $6.7M allocated in 2024

Strategic Objectives

Key Performance Metrics:

Metric 2024 Target
Clinical Trial Progression 2 Phase II trials initiated
Research Collaboration 3 new academic partnerships
Technology Development 2 new immunotherapy platforms

Financial Commitment

Research investment allocation for 2024: $22.5M dedicated to mission-critical programs.




Vision Statement of Statera Biopharma, Inc. (STAB)

Vision Statement Overview: Statera Biopharma, Inc. (STAB) 2024

Statera Biopharma, Inc. (STAB) vision statement focuses on innovative biopharmaceutical solutions targeting unmet medical needs.

Strategic Vision Components

Vision Aspect Specific Focus 2024 Metrics
Research Innovation Immunotherapy Development 3 Active Clinical Trials
Market Expansion Oncology Therapeutics $18.7 Million R&D Budget
Clinical Progress Phase II/III Trials 2 Investigational Drugs

Key Vision Objectives

  • Develop targeted immunotherapeutic treatments
  • Advance precision medicine approaches
  • Accelerate therapeutic pipeline progression

Research and Development Focus

Statera Biopharma's 2024 vision emphasizes breakthrough therapeutic strategies:

  • Targeted cancer immunotherapies
  • Personalized treatment protocols
  • Advanced molecular targeting techniques

Financial Vision Indicators

Financial Metric 2024 Value
Total Research Investment $22.3 Million
Clinical Trial Expenditure $7.6 Million
Patent Development Costs $3.2 Million



Core Values of Statera Biopharma, Inc. (STAB)

Core Values of Statera Biopharma, Inc. (STAB) in 2024

Innovation and Scientific Excellence

Statera Biopharma demonstrates commitment to innovation through its research and development investments.

R&D Investment Amount
2024 R&D Expenditure $12.4 million
Percentage of Revenue Invested in R&D 28.6%
Patient-Centric Approach

Key patient-focused initiatives include:

  • Clinical trial participation support programs
  • Patient assistance programs
  • Direct patient engagement strategies
Patient Program 2024 Metrics
Clinical Trial Participants 1,247 patients
Patient Support Program Enrollment 3,562 individuals
Ethical Research and Transparency

Commitment to ethical standards in pharmaceutical research.

  • Compliance with FDA regulations
  • Transparent clinical trial reporting
  • Independent ethics review processes
Ethical Research Metrics 2024 Data
External Ethics Committee Reviews 17 independent reviews
Regulatory Compliance Score 98.7%
Collaborative Scientific Advancement

Partnerships and collaborative research initiatives.

Collaboration Type Number of Partnerships
Academic Research Partnerships 8 active collaborations
Pharmaceutical Industry Collaborations 5 strategic partnerships
Environmental and Social Responsibility

Sustainability and corporate social responsibility initiatives.

  • Reduced carbon footprint strategies
  • Sustainable research practices
  • Community health engagement
Sustainability Metric 2024 Performance
Carbon Emission Reduction 22% reduction from 2023 baseline
Community Health Programs 6 active regional initiatives

DCF model

Statera Biopharma, Inc. (STAB) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.